Information de reference pour ce titreAccession Number: | 01857036-201803000-00015.
|
Author: | de Boer, Mintsje MD 1; van Leeuwen, Flora E. PhD 2; Hauptmann, Michael PhD 2; Overbeek, Lucy I. H. PhD 3; de Boer, Jan Paul MD; PhD 4; Hijmering, Nathalie J. MSc 5; Sernee, Arthur MSc 5; Klazen, Caroline A. H. MD; PhD 6; Lobbes, Marc B. I. MD; PhD 7; van der Hulst, Rene R. W. J. MD; PhD 8; Rakhorst, Hinne A. MD; PhD 9; de Jong, Daphne MD; PhD 5
|
Institution: | (1)Plastic, Reconstructive and Hand-Surgery, Maastricht University Medical Centre, School for Oncology and Developmental Biology, Maastricht, the Netherlands (2)Department of Epidemiology and Biostatistics, Netherlands Cancer Institute, Amsterdam, the Netherlands (3)Dutch Nationwide Network and Registry of Histo- and Cytopathology, Houten, the Netherlands (4)Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands (5)Department of Pathology, VU University Medical Centre, Amsterdam, the Netherlands (6)Department of Radiology, Medisch Spectrum Twente, Enschede, the Netherlands (7)Department of Radiology and Nuclear Medicine, Maastricht University, Maastricht University Medical Centre, Maastricht, the Netherlands (8)Plastic, Reconstructive and Hand-Surgery, Maastricht, University Medical Centre, School of Nutrition and Translational, Research in Metabolism, Maastricht, the Netherlands (9)Department of Plastic, Reconstructive and Hand Surgery, Ziekenhuis Groep Twente/Medisch Spectrum Twente, Enschede, the Netherlands
|
Title: | |
Source: | JAMA Oncology. 4(3):335-341, March 2018.
|
Abstract: | Importance: Breast implants are among the most commonly used medical devices. Since 2008, the number of women with breast implants diagnosed with anaplastic large-cell lymphoma in the breast (breast-ALCL) has increased, and several reports have suggested an association between breast implants and risk of breast-ALCL. However, relative and absolute risks of breast-ALCL in women with implants are still unknown, precluding evidence-based counseling about implants.
Objective: To determine relative and absolute risks of breast-ALCL in women with breast implants.
Design, Setting, and Participants: Through the population-based nationwide Dutch pathology registry we identified all patients diagnosed with primary non-Hodgkin lymphoma in the breast between 1990 and 2016 and retrieved clinical data, including breast implant status, from the treating physicians. We estimated the odds ratio (OR) of ALCL associated with breast implants in a case-control design, comparing implant prevalence between women with breast-ALCL and women with other types of breast lymphoma. Cumulative risk of breast-ALCL was derived from the age-specific prevalence of breast implants in Dutch women, estimated from an examination of 3000 chest x-rays and time trends from implant sales.
Main Outcomes and Measures: Relative and absolute risks of breast-ALCL in women with breast implants.
Results: Among 43 patients with breast-ALCL (median age, 59 years), 32 had ipsilateral breast implants, compared with 1 among 146 women with other primary breast lymphomas (OR, 421.8; 95% CI, 52.6-3385.2). Implants among breast-ALCL cases were more often macrotextured (23 macrotextured of 28 total implants of known type, 82%) than expected (49 193 sold macrotextured implants of total sold 109 449 between 2010 and 2015, 45%) based on sales data (P < .001). The estimated prevalence of breast implants in women aged 20 to 70 years was 3.3%. Cumulative risks of breast-ALCL in women with implants were 29 per million at 50 years and 82 per million at 70 years. The number of women with implants needed to cause 1 breast-ALCL case before age 75 years was 6920.
Conclusions and Relevance: Breast implants are associated with increased risk of breast-ALCL, but the absolute risk remains small. Our results emphasize the need for increased awareness among the public, medical professionals, and regulatory bodies, promotion of alternative cosmetic procedures, and alertness to signs and symptoms of breast-ALCL in women with implants.
Copyright 2018 by the American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use. American Medical Association, 515 N. State St, Chicago, IL 60610.
|
References: | 1. Angell M. Shattuck Lecture-evaluating the health risks of breast implants: the interplay of medical science, the law, and public opinion. N Engl J Med. 1996;334(23):1513-1518.
2. Balk EM, Earley A, Avendano EA, Raman G. Long-term health outcomes in women with silicone gel breast implants: a systematic review. Ann Intern Med. 2016;164(3):164-175.
3. Janowsky EC, Kupper LL, Hulka BS. Meta-analyses of the relation between silicone breast implants and the risk of connective-tissue diseases. N Engl J Med. 2000;342(11):781-790.
4. de Jong D, Vasmel WL, de Boer JP, et al. Anaplastic large-cell lymphoma in women with breast implants. JAMA. 2008;300(17):2030-2035.
5. Brody GS, Deapen D, Taylor CR, et al. Anaplastic large cell lymphoma occurring in women with breast implants: analysis of 173 cases. Plast Reconstr Surg. 2015;135(3):695-705.
6. Medical Device Reports of Breast Implant-Associated Anaplastic Large Cell Lymphoma. Silver Spring, Maryland, U.S. Food & Drug Administration (FDA), 2017. https://www.fda.gov/MedicalDevic...- ouverture dans une nouvelle fenêtre. Accessed March 23, 2017.
7. Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375-2390.
8. Doren EL, Miranda RN, Selber JC, et al. U.S. epidemiology of breast implant-associated anaplastic large cell lymphoma. Plast Reconstr Surg. 2017;139(5):1042-1050.
9. Loch-Wilkinson A, Beath KJ, Knight RJW, et al. Breast implant associated anaplastic large cell lymphoma in Australia and New Zealand-high surface area textured implants are associated with increased risk. Plast Reconstr Surg. 2017;140(4):645-654.
10. Casparie M, Tiebosch AT, Burger G, et al. Pathology databanking and biobanking in The Netherlands, a central role for PALGA, the nationwide histopathology and cytopathology data network and archive. Cell Oncol. 2007;29(1):19-24.
11. Miranda RN, Aladily TN, Prince HM, et al. Breast implant-associated anaplastic large-cell lymphoma: long-term follow-up of 60 patients. J Clin Oncol. 2014;32(2):114-120.
12. Paap E, Witjes M, van Landsveld-Verhoeven C, Pijnappel RM, Maas AH, Broeders MJ. Mammography in females with an implanted medical device: impact on image quality, pain and anxiety. Br J Radiol. 2016;89(1066):20160142.
13. Fracheboud J, de Koning HJ, Boer R, et alNational Evaluation Team for Breast cancer screening in The Netherlands. Nationwide breast cancer screening programme fully implemented in The Netherlands. Breast. 2001;10(1):6-11.
14. Kim HJ, Fay MP, Feuer EJ, Midthune DN. Permutation tests for joinpoint regression with applications to cancer rates. Stat Med. 2000;19(3):335-351.
15. Population in the Netherlands; by sex and age and marital status, 1 January, 1950-2016. Heerlen, the Netherlands: Statistics Netherlands, 2017. http://statline.cbs.nl/Statweb/- ouverture dans une nouvelle fenêtre. Accessed February 13, 2017.
16. Schouten LJ, Straatman H, Kiemeney LA, Verbeek AL. Cancer incidence: life table risk versus cumulative risk. J Epidemiol Community Health. 1994;48(6):596-600.
17. SAS Institute Inc. 2011. Base SAS 9.3 Procedures Guide. Cary, NC.
18. De Boer M, van der Sluis WB, de Boer JP, et al. BIA-ALCL in a transgender woman. Aesthet Surg J. 2017;37(8):NP83-NP87.
19. Blombery P, Thompson ER, Jones K, et al. Whole exome sequencing reveals activating JAK1 and STAT3 mutations in breast implant-associated anaplastic large cell lymphoma anaplastic large cell lymphoma. Haematologica. 2016;101(9):e387-e390.
20. Kadin ME, Deva A, Xu H, et al. Biomarkers provide clues to early events in the pathogenesis of breast implant-associated anaplastic large cell lymphoma. Aesthet Surg J. 2016;36(7):773-781.
21. Hu H, Johani K, Almatroudi A, et al. Bacterial biofilm infection detected in breast implant associated anaplastic large cell lymphoma. Plast Reconstr Surg. 2016;137(6):1659-1669.
22. Ye X, Shokrollahi K, Rozen WM, et al. Anaplastic large cell lymphoma (ALCL) and breast implants: breaking down the evidence. Mutat Res Rev Mutat Res. 2014;762:123-132.
23. Thomas A, Link BK, Altekruse S, Romitti PA, Schroeder MC. Primary breast lymphoma in the United States: 1975-2013. J Natl Cancer Inst. 2017;109(6).
24. Deva AK. Discussion: U.S. Epidemiology of Breast Implant-Associated Anaplastic Large-Cell Lymphoma. Plast Reconstr Surg. 2017;139(5):1051-1052.
25. Khouri RK, Rigotti G, Khouri RK Jr, et al. Tissue-engineered breast reconstruction with Brava-assisted fat grafting: a 7-year, 488-patient, multicenter experience. Plast Reconstr Surg. 2015;135(3):643-658.
26. Tuinder S, Baetens T, De Haan MW, et al. Septocutaneous tensor fasciae latae perforator flap for breast reconstruction: radiological considerations and clinical cases. J Plast Reconstr Aesthet Surg. 2014;67(9):1248-1256.
27. Faris O, Shuren J. An FDA Viewpoint on Unique Considerations for Medical-Device Clinical Trials. N Engl J Med. 2017;376(14):1350-1357.
|
Language: | English.
|
Document Type: | Research: Original Investigation.
|
Journal Subset: | Clinical Medicine.
|
ISSN: | 2374-2437
|
DOI Number: | https://dx.doi.org/10.1001/jamao...- ouverture dans une nouvelle fenêtre
|
Annotation(s) | |
|
|